Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for WindowsUnbound PubMed app for MAC OS Yosemite Macbook Air pro
(Prog Urol[TA])
4,991 results
  • [Prognostic value of testosterone during androgene deprivation therapy]. [Journal Article]
  • PUProg Urol 2019 Jul 13
  • Vallat A, Pillot P, … Irani J
  • CONCLUSIONS: This study did not show any link between testosterone levels at the end of the first off-treatment phase (before reintroducing ADT) and overall survival, metastasis-free survival and CRPC-free survival. Likewise, it was not associated with the frequency of adverse events or cancer-related complications. Initial ADT duration was not linked to CRPC occurrence or IADT chronological parameters.
  • [Oligometastatic prostate cancer management]. [Journal Article]
  • PUProg Urol 2019; 29 Suppl 1:S20-S34
  • Kleinclauss F, Thiery-VuiUemin A
  • CONCLUSIONS: In absence of consensus or guidelines, management of prostate cancer should be an individualized, patient-based management taking into account primary tumor stage and grade, number and types of metastasis and patient characteristics.
  • [Nuclear medicine for prostate cancer management]. [Journal Article]
  • PUProg Urol 2019; 29 Suppl 1:S2-S7
  • Erra B, Pradere B
  • Nuclear medicine is a keystone specialty in the evaluation and management of prostate cancer. Its recent development, particularly through metabolic imaging and isotope therapy, has made it a major g…
New Search Next